Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patient with at least 1-year history of migraines (with or without aura) including the following:~  * Migraine attacks more than 1 year with age of onset prior to 50 years of age~ * Migraine attacks, on average, last about 4 - 72 hours if untreated~ * No more than 8 attacks of moderate to severe intensity per month within last 3 months~ * Patient must be able to distinguish migraine attacks from tension/cluster attacks and must have consistent migraine headaches of at least 2 migraine headaches attacks of moderate to severe intensity in each of the last 3 months~ * Less than 15 days of headache (migraine or non-migraine) per month in each of 3 months prior to screening~* Male and female ≥ 18 years and ≤ age 65~* No clinically significant abnormality identified on the medical or laboratory evaluation~Key Exclusion Criteria:~* Patient has a history of basilar migraine or hemiplegic migraine~* Patient does not receive migraine relief from triptan migraine treatment~* Medications that may alter the pH of the stomach (acid reducing agents), such as H-2 antagonists, Proton Pump inhibitors (PPI), antacids~* History of ergotamine or triptan intake greater than/equal 10 days per month on a regular basis for greater than 3 months~* History of non-narcotic analgesic intake on greater then/equal 15 days per month for greater than/equal 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A: Rimegepant, 10 mg (Type: EXPERIMENTAL): Participants received a single dose (one capsule) of rimegepant 10 milligram (mg) orally and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
- Treatment B: Rimegepant, 25 mg (Type: EXPERIMENTAL): Participants received a single dose (one capsule) of rimegepant 25 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
- Treatment C: Rimegepant, 75 mg (Type: EXPERIMENTAL): Participants received a single dose (one capsule) of rimegepant 75 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
- Treatment D: Rimegepant, 150 mg (Type: EXPERIMENTAL): Participants received a single dose (one capsule) of rimegepant 150 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
- Treatment E: Rimegepant, 300 mg (Type: EXPERIMENTAL): Participants received a single dose (two 150 mg capsules) of rimegepant 300 mg orally; and two rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
- Treatment F: Rimegepant, 600 mg (Type: EXPERIMENTAL): Participants received a single dose (four capsules of 150 mg each) of rimegepant 600 mg orally; anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
- Treatment P: Rimegepant Placebo-Matching Capsules (Type: PLACEBO_COMPARATOR): Participants received a single dose (4 capsules) of rimegepant placebo-matching capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
- Treatment G: Sumatriptan 100 mg (Type: ACTIVE_COMPARATOR): Participants received a single dose (one capsule) of rimegepant-matching sumatriptan 100 mg orally and three rimegepant matching placebo capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.

Based on this trial design, predict the completion outcome and termination type (if applicable).